TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms - Schimmer Roman R; Kovtonyuk Larisa V; Klemm Nancy; Fullin Jonas; Stolz Sebastian M; Mueller Jan; Caiado Francisco; Kurppa Kari J; Ebert Benjamin L; Manz Markus G; Boettcher Steffen (Elsevier, 2022)